This review explained the changes in lower urinary tract symptoms (LUTS) and quality of life (QoL) that occurred over time in patients with prostate cancer following radical prostatectomy (RP; removal of the prostate). The data showed that 6 to 12 months are required for LUTS improvement after RT.

This study compared the surgical, functional, and oncological outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer (PCa) with a large prostate volume. The study found that RARP was associated with better surgical, functional, and oncological outcomes compared to LRP in these patients.

This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations.

This study evaluated the long-term functional and oncological outcomes of robotic-assisted laparoscopic radical prostatectomy (RALP) and open retropubic radical prostatectomy (RRP) for the treatment of patients with localized prostate cancer (PCa). This study found that RALP was associated with better oncological outcomes compared to RRP over the long term.

This article reviewed new studies on focal therapy (FT) in patients with localized prostate cancer (PCa), with a focus on treatment effectiveness. 

This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).  

This study reported the long-term effects on the health-related quality of life (HR-QoL) of apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The data showed that apalutamide plus ADT preserved HR-QoL in these patients.

This study compared the outcomes between radical prostatectomy (RP; prostate-removal surgery) and different types of radiotherapy (RT) in older patients with localized prostate cancer (PCa). The study found that RT offers similar cancer-specific outcomes to RP for low- to intermediate-risk patients.

This study evaluated the effectiveness and safety outcomes of talazoparib (Talzenna) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in DNA repair genes. The data showed that talazoparib was effective with manageable side effects for these patients.

This article looked at the impact of nerve-sparing (NS) surgery on positive surgical margin (PSM) location and the recurrence of tumors in patients following radical prostatectomy (RP; prostate removal surgery). The authors found that having NS surgery on both sides of the prostate increased the risk of PSM and was associated with a higher rate of tumor recurrence.